Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The serotonin transporter (SERT) and norepinephrine transporter (NET) are sodium-dependent neurotransmitter transporters responsible for the reuptake of released serotonin and norepinephrine, respectively, into nerve terminals in the brain. These transporters play key roles in spatiotemporal regulation of neurotransmission, maintenance of extrasynaptic monoamine levels, and pre-synaptic monoamine homeostasis. They are important targets for antidepressant medications, particularly serotonin-norepinephrine reuptake inhibitors (SNRIs), which block the reuptake of both serotonin and norepinephrine, thereby increasing their availability in the synaptic cleft. This dual inhibition can offer advantages over single-neurotransmitter targeting drugs by addressing a wider range of symptoms, especially in conditions involving both mood disorders and pain.
Inhibition of serotonin and norepinephrine reuptake from synaptic cleft, blocking reabsorption of neurotransmitters, and increasing availability of serotonin and norepinephrine in the brain.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Serotonin and Norepinephrine Transporters (SERT and NET).